IKT Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical stage pharmaceutical company that is engaged in developing therapeutics for neurodegenerative disease inside and outside of the brain. The company develops IkT-148009, a brain penetrant c-Abl protein kinase inhibitor which is under phase I trial for Parkinson's disease (PD) and to treat early-stage PD patients with GI complications, as well as for the treatment of dysphagia and neurogenic constipation. Its clinical development product includes IkT-001Pro, an Abl kinase inhibitor prodrug of the anticancer agent for chronic myelogenous leukemia; and research phase products include IkT-01427 for progressive multifocal leukoencephalopathy, as well as IKT-148X to treat dementia with lewy body and multiple system atrophy. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; the M. D. Anderson Cancer Center; and Memorial Sloan-Kettering Cancer Center. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.
$0.72 +0.00 (0.63%)
As of 03/24/2023 16:00:01 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation: USA
IPO date: 12/23/2020
Outstanding shares: 28,027,840
Average volume: 563,479
Market cap: $20,053,920
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%